Lords Mark Expands Healthcare, Restructures Energy Business
Lords Mark Industries Ltd announced significant business developments across its diagnostics, medical devices, healthcare delivery, and renewable energy segments. The company projects consolidated revenue of at least ₹1,550 crore and PAT of ₹178 crore by FY2027, with substantial growth expected from FY2028 onwards driven by new ventures like sickle cell testing and medical devices. A key strategic move involves the proposed demerger of its renewable energy and LED division into a new entity, Lords Shakti Power Limited, by March 2027. Additionally, Lords Mark is entering into an exclusive agreement for CAR-T cell therapy in India, establishing a subsidiary in the UK and Switzerland for diagnostics, and launching oncology hospitals and a dialysis center network. These initiatives aim to broaden the healthcare platform and unlock value from its energy business.
Key Highlights
- FY2027 revenue target of ₹1,550 crore, PAT ₹178 crore.
- Renewable energy division to be demerged into Lords Shakti Power.
- Exclusive CAR-T cell therapy agreement for India.
- New subsidiaries established in UK and Switzerland.
- Expansion into oncology hospitals and dialysis centers planned.
Price Impact
More from LORDSMARK